The Priority Review

Tag

EloraTZP

2 stories

  1. Clinical trials

    Eli Lilly registers Phase 3 study of EloraTZP in obesity

    The study, NCT07881432 (AMPLIFY-1), was first posted on ClinicalTrials.gov on October 19, 2026. It plans to enroll 2115 participants, start in December 2026, and reach primary completion in October 2029.

  2. Clinical trials

    Eli Lilly registers Phase 3 study of EloraTZP in obesity and type 2 diabetes

    The study plans to enroll 1000 participants, start in November 2026, and reach primary completion in October 2029. It aims to investigate the efficacy and safety of the eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide in adults with obesity or overweight and type 2 diabetes.